BACKGROUND Coats disease is an idiopathic exudative outer retinopathy caused by abnormalretinal vascular development.AIM To evaluate the long-term outcomes of intravitreal conbercept injection with laserphotocoagulati...BACKGROUND Coats disease is an idiopathic exudative outer retinopathy caused by abnormalretinal vascular development.AIM To evaluate the long-term outcomes of intravitreal conbercept injection with laserphotocoagulation as a treatment for Coats disease in adults.METHODS This retrospective case series study included patients diagnosed with Coatsdisease and treated with intravitreal conbercept injection and 532-nm laserphotocoagulation at the Ophthalmology Department of Shenzhen People’sHospital between January 2016 and January 2017. Best-corrected visual acuity(BCVA) measurements, noncontact tonometry, ophthalmoscopy, fundusphotography, fundus fluorescein angiography and optical coherence tomographywere performed before treatment and at 1 wk, 1 mo, 3 mo, 6 mo, 9 mo, 12 mo, 24mo and 36 mo after therapy. Best-corrected visual acuity was measured using theearly treatment of diabetic retinopathy study chart.RESULTS The study included eight eyes of 8 patients (7 men) aged 36.10 ± 6.65 years. Theaverage BCVA of the affected eye before treatment was 51.17 ± 15.15 letters(range, 28–70 letters), and the average central macular thickness was 303.30 ±107.87 μm (range, 221–673 μm). Four eyes were injected once, three were injectedtwice, and one was injected three times. Average follow-up duration was 37.33 ±2.26 mo. Average BCVA of the affected eye was 51.17 ± 15.15 letters before treatment and was increased by 13.50 ± 3.20, 16.25 ± 7.73, 18.25 ± 8.96, 18.03 ± 5.27,18.63 ± 3.35, 19.75 ± 6.96, 18.05 ± 5.36 and 17.88 ± 3.45 letters at 1 wk, 1 mo, 3 mo, 6mo, 9 mo, 12 mo, 24 mo and 36 mo after treatment, respectively (P < 0.01). Thepatients showed varying degrees of subretinal fluid resorption after treatment.None of the patients had serious complications such as increased intraocularpressure, development/progression of cataracts, endophthalmitis or retinaldetachment.CONCLUSION Intravitreal injection of conbercept combined with 532-nm laser photocoagulationmay be a feasible treatment for Coats disease in adult patients.展开更多
基金Supported by the Shenzhen Municipal Health and Family Planning System Research Project,No.SZFZ2017085.
文摘BACKGROUND Coats disease is an idiopathic exudative outer retinopathy caused by abnormalretinal vascular development.AIM To evaluate the long-term outcomes of intravitreal conbercept injection with laserphotocoagulation as a treatment for Coats disease in adults.METHODS This retrospective case series study included patients diagnosed with Coatsdisease and treated with intravitreal conbercept injection and 532-nm laserphotocoagulation at the Ophthalmology Department of Shenzhen People’sHospital between January 2016 and January 2017. Best-corrected visual acuity(BCVA) measurements, noncontact tonometry, ophthalmoscopy, fundusphotography, fundus fluorescein angiography and optical coherence tomographywere performed before treatment and at 1 wk, 1 mo, 3 mo, 6 mo, 9 mo, 12 mo, 24mo and 36 mo after therapy. Best-corrected visual acuity was measured using theearly treatment of diabetic retinopathy study chart.RESULTS The study included eight eyes of 8 patients (7 men) aged 36.10 ± 6.65 years. Theaverage BCVA of the affected eye before treatment was 51.17 ± 15.15 letters(range, 28–70 letters), and the average central macular thickness was 303.30 ±107.87 μm (range, 221–673 μm). Four eyes were injected once, three were injectedtwice, and one was injected three times. Average follow-up duration was 37.33 ±2.26 mo. Average BCVA of the affected eye was 51.17 ± 15.15 letters before treatment and was increased by 13.50 ± 3.20, 16.25 ± 7.73, 18.25 ± 8.96, 18.03 ± 5.27,18.63 ± 3.35, 19.75 ± 6.96, 18.05 ± 5.36 and 17.88 ± 3.45 letters at 1 wk, 1 mo, 3 mo, 6mo, 9 mo, 12 mo, 24 mo and 36 mo after treatment, respectively (P < 0.01). Thepatients showed varying degrees of subretinal fluid resorption after treatment.None of the patients had serious complications such as increased intraocularpressure, development/progression of cataracts, endophthalmitis or retinaldetachment.CONCLUSION Intravitreal injection of conbercept combined with 532-nm laser photocoagulationmay be a feasible treatment for Coats disease in adult patients.
